JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Squamous Cell

Interventions

DRUG: JNJ-90301900 (NBTXR3)
DRUG: Cetuximab
RADIATION: Radiation Therapy

Sponsor

Johnson & Johnson Enterprise Innovation Inc.